139 related articles for article (PubMed ID: 30968601)
1. Changes of clinical symptoms in patients with new psychoactive substance (NPS)-related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction.
Funada D; Matsumoto T; Tanibuchi Y; Kawasoe Y; Sakakibara S; Naruse N; Ikeda S; Sunami T; Muto T; Cho T
Neuropsychopharmacol Rep; 2019 Jun; 39(2):119-129. PubMed ID: 30968601
[TBL] [Abstract][Full Text] [Related]
2. Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.
Matsumoto T; Tachimori H; Takano A; Tanibuchi Y; Funada D; Wada K
Psychiatry Clin Neurosci; 2016 Dec; 70(12):560-566. PubMed ID: 27527499
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
[TBL] [Abstract][Full Text] [Related]
4. The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.
Tanibuchi Y; Matsumoto T; Funada D; Shimane T
Neuropsychopharmacol Rep; 2018 Dec; 38(4):189-196. PubMed ID: 30341809
[TBL] [Abstract][Full Text] [Related]
5. Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data.
Smyth BP; Lyons S; Cullen W
Drug Alcohol Rev; 2017 Sep; 36(5):609-617. PubMed ID: 28419577
[TBL] [Abstract][Full Text] [Related]
6. Legislation targeting head shops selling new psychoactive substances and changes in drug-related psychiatric admissions: A national database study.
Smyth BP; Daly A; Elmusharaf K; McDonald C; Clarke M; Craig S; Cullen W
Early Interv Psychiatry; 2020 Feb; 14(1):53-60. PubMed ID: 30945460
[TBL] [Abstract][Full Text] [Related]
7. Acute neurological consequences of novel psychoactive substance use: a retrospective review in a large UK hospital.
Tanti M; Cosgrove J; Kelleher C; Jones R; Maguire M
Clin Med (Lond); 2021 May; 21(3):189-194. PubMed ID: 33947659
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
[TBL] [Abstract][Full Text] [Related]
9. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
Scherbaum N; Schifano F; Bonnet U
Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
[TBL] [Abstract][Full Text] [Related]
10. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of quasi-legal psychoactive substance use among male patients in HIV care in Japan: a cross-sectional study.
Hayashi K; Wakabayashi C; Ikushima Y; Tarui M
Subst Abuse Treat Prev Policy; 2017 Feb; 12(1):11. PubMed ID: 28231843
[TBL] [Abstract][Full Text] [Related]
12. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project.
Beck O; Franzén L; Bäckberg M; Signell P; Helander A
Clin Toxicol (Phila); 2016 Aug; 54(7):568-75. PubMed ID: 27412885
[TBL] [Abstract][Full Text] [Related]
13. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
[TBL] [Abstract][Full Text] [Related]
14. [Current situation and clinical characteristics of sedative-related disorder patients in Japan: a comparison with methamphetamine-related disorder patients].
Matsumoto T; Ozaki S; Kobayashi O; Wada K
Seishin Shinkeigaku Zasshi; 2011; 113(12):1184-98. PubMed ID: 22352004
[TBL] [Abstract][Full Text] [Related]
15. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study.
Ryu SH; Katona C; Rive B; Livingston G
Am J Geriatr Psychiatry; 2005 Nov; 13(11):976-83. PubMed ID: 16286441
[TBL] [Abstract][Full Text] [Related]
16. Locked in and Growing Old: The Psychiatric, Forensic, and Cognitive Correlates of 30 Years of Psychiatric Hospitalization.
Hives F; Karyadi KA; Nitch S; Kinney D
Am J Geriatr Psychiatry; 2018 Feb; 26(2):188-197. PubMed ID: 29122420
[TBL] [Abstract][Full Text] [Related]
17. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
Helander A; Bäckberg M; Beck O
PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
[TBL] [Abstract][Full Text] [Related]
18. Head shops and new psychoactive substances: a public health perspective.
Smyth BP
Ir J Psychol Med; 2023 Mar; 40(1):89-96. PubMed ID: 33478611
[TBL] [Abstract][Full Text] [Related]
19. Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study.
White JC; Wood DM; Hill SL; Eddleston M; Officer J; Dargan PI; Dunn M; Thomas SHL
Clin Toxicol (Phila); 2019 Jul; 57(7):663-667. PubMed ID: 30676081
[No Abstract] [Full Text] [Related]
20. The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study.
Hallikainen I; Hongisto K; Välimäki T; Hänninen T; Martikainen J; Koivisto AM
J Alzheimers Dis; 2018; 61(4):1367-1376. PubMed ID: 29376861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
